Immuno-Oncology

Here is your snapshot for all therapeutic options that were cleared by the FDA in April 2025 spanning tumor types.

Invikafusp alfa was active in unresectable, locally advanced or metastatic solid tumors resistant to immune checkpoint inhibitors.

Perioperative pembrolizumab with postoperative radiation with or without cisplatin showed durable EFS in resectable, locally advanced HNSCC.

Sasanlimab plus BCG significantly improved EFS vs BCG alone in high-risk non–muscle-invasive bladder cancer.

Penpulimab gets green light from FDA for nasopharyngeal carcinoma, sacituzumab govitecan combination boosts PFS in TNBC, and more.

Ivonescimab plus chemotherapy met the primary PFS end point vs tislelizumab plus chemotherapy in advanced squamous NSCLC.

Pembrolizumab/chemotherapy was approved by Health Canada for the treatment of patients with unresectable advanced or metastatic pleural mesothelioma.

The top 5 OncLive videos of the week cover insights in multiple myeloma, AL amyloidosis, myelofibrosis, breast cancer, and sarcoma.

In this episode, experts discuss the impact of neoadjuvant radiation and immunotherapy on surgical planning in patients with soft tissue sarcomas.

The PD-L1 IHC 22C3 pharmDx assay has been granted European IVDR certification for identifying pembrolizumab eligibility in gastric/GEJ adenocarcinoma.

Nerea Lopetegui-Lia, MD, discusses the prevalence of and risk factors for triple-negative breast cancer, and strategies that may improve survival outcomes.

Response-adapted treatment with nivolumab with or without rituximab produced responses in treatment-naive follicular lymphoma.

Linda R. Duska, MD, MPH, contextualizes updated OS and PFS2 findings from the second interim analysis of KEYNOTE-A18 in locally advanced cervical cancer.

Nivolumab/ipilimumab is approved for dMMR/MSI-H mCRC and unresectable or metastatic HCC, larotrectinib wins full approval in NTRK+ solid tumors, and more.

Durvalumab received approval from Health Canada for patients with LS-SCLC whose disease has not progressed after platinum-based chemoradiation.

María-Victoria Mateos, MD, PhD, discusses next steps for evaluating the role of cilta-cel in lenalidomide-refractory and other multiple myeloma subtypes.

Subcutaneous and intravenous pembrolizumab provided comparable efficacy and safety in patients with previously untreated, metastatic non–small cell lung cancer.

Clonal neoantigen load was significantly associated with promising responses to PD-1/PD-L1 and CTLA-4 combination therapy in RCC.

Here is your Q2 2025 preview spotlighting 7 FDA decisions to watch, including upcoming PDUFAs for nivolumab/ipilimumab, belzutifan, UGN-102, avutometinib/defactinib, and more.

Durvalumab has received perioperative approval in the European Union in patients with resectable non–small cell lung cancer based on data from AEGEAN.

Here is your snapshot for all therapeutic options that were approved by the FDA in March 2025 spanning tumor types.

Tisotumab vedotin was granted approval by the EU for recurrent or metastatic cervical cancer with disease progression on or after chemotherapy.

María-Victoria Mateos, MD, PhD, discusses long-term OS data from the CARTITUDE-4 trial of cilta-cel in lenalidomide-refractory multiple myeloma.

Updated KEYNOTE-799 data continued to show robust activity with pembrolizumab plus concurrent chemoradiation in unresectable stage III NSCLC.

The FDA cleared therapeutic options in pNETs/epNETs, MIBC, and mCRPC; experts highlight top abstracts ahead of 2025 EBMT; and more from OncLive.